Welcome to our dedicated page for Salarius Pharmaceuticals SEC filings (Ticker: SLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking seclidemstat trial costs or SP-3164 development milestones inside a 300-page report isn’t easy. Anyone searching for “Salarius Pharmaceuticals SEC filings explained simply” or wondering how to read a “Salarius Pharmaceuticals annual report 10-K simplified” is really asking for clarity behind the science-heavy disclosures. Stock Titan delivers that clarity.
Every document hits our feed the moment it’s posted to EDGAR—whether it’s a “Salarius Pharmaceuticals quarterly earnings report 10-Q filing”, an unexpected “Salarius Pharmaceuticals 8-K material events explained” alert on a licensing deal, or the “Salarius Pharmaceuticals insider trading Form 4 transactions” that hint at management’s confidence. Our AI-powered summaries translate technical language into plain English, flagging R&D expense tables, cash-runway metrics and milestone-payment clauses. You’ll even see a dedicated stream for “Salarius Pharmaceuticals Form 4 insider transactions real-time” alongside color-coded charts that make a “Salarius Pharmaceuticals earnings report filing analysis” effortless.
Ready to start understanding Salarius Pharmaceuticals SEC documents with AI? With comprehensive coverage of everything from the “Salarius Pharmaceuticals proxy statement executive compensation” to shelf registrations for future capital raises, you can:
- Monitor “Salarius Pharmaceuticals executive stock transactions Form 4” before pivotal readouts
- Compare quarter-over-quarter burn rates without manual number-crunching
- Stay ahead of clinical-trial announcements and collaboration disclosures
All filings update in real time, and expert commentary spotlights the sections that matter most to oncology-focused investors—so you spend minutes, not hours, decoding complex biotech documents.
Salarius Pharmaceuticals, Inc. ("SLRX") filed an 8-K to report that on 10 July 2025 it received a decision from the Nasdaq Hearings Panel granting additional time to regain listing compliance.
- Equity Standard – Rule 5550(b)(1): deadline extended from early-July to late-July 2025.
- Minimum Bid Price – Rule 5550(a)(2): deadline remains early-August 2025.
Background events include a March 26 2025 notice that stockholders’ equity fell below the required threshold and an April 23 2025 delisting notice for trading below the $1.00 bid-price minimum for 30 consecutive business days. Because Salarius completed a reverse stock split within the prior year, it was ineligible for the usual 180-day cure period.
The company appealed, automatically staying delisting. A prior extension was granted on 11 June 2025; the latest ruling lengthens only the equity-compliance deadline and is contingent on milestone reporting. Failure to meet either requirement by the new dates is expected to lead to suspension and delisting from The Nasdaq Capital Market.
No operating results, financing transactions, or strategic updates were provided; the filing focuses solely on Nasdaq listing status.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) convened a Special Meeting of Stockholders on July 8, 2025. Of the 2,127,286 common shares outstanding on the May 13, 2025 record date, 789,213 shares (37.10%) were present in person or by proxy, satisfying quorum requirements.
Key matters approved
- Reverse Stock Split: Stockholders authorized the Board to implement a reverse split in a ratio between 1-for-4 and 1-for-40 at the Board’s discretion (Votes For: 561,364; Against: 224,901; Abstain: 2,678).
- Nasdaq 20% Issuance: Approved issuance of additional common shares under the December 12, 2024 Securities Purchase Agreement with C/M Capital Master Fund, LP without the exchange-cap limitation, satisfying Nasdaq Listing Rules 5635(a) & 5635(d) (Votes For: 124,631; Against: 73,764; Abstain: 1,095; Broker Non-Votes: 589,723).
- Adjournment Proposal: Granted authority to adjourn the meeting to solicit more proxies if needed (Votes For: 598,521; Against: 187,750; Abstain: 2,942). An adjournment ultimately was not required.
No other matters were brought before the meeting, and the filing contains no financial performance data. The Board now possesses flexibility to manage share structure (reverse split) and finalize the previously agreed financing transaction, both of which can influence future capitalization and compliance with Nasdaq listing standards.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
What is the primary focus of Salarius Pharmaceuticals Inc?
Which therapeutic approaches does the company utilize?
What are the main drug candidates in their pipeline?
How does Salarius differentiate itself in the competitive oncology market?
What role does targeted gene dysregulation play in their treatment strategies?
How is the company integrating innovative technologies into its drug development?
What can be understood about their strategic collaboration with Decoy Therapeutics?
How do the company's initiatives contribute to addressing unmet medical needs in oncology?
